- CureToday.com
- OncLive.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Lisa Astor | Authors
Articles
Positive Efficacy Data Found With Lifileucel TIL Therapy for Pretreated Advanced Melanoma
April 11, 2021
Lifileucel (LN-144), the tumor-infiltrating lymphocyte therapy, showed a positive objective response rate with the median duration of response not yet reached after more than 28 months of follow-up in patients with advanced melanoma.
Platinum-Sensitive Relapsed Ovarian Cancer Derives Benefit from Maintenance Olaparib, Regardless of Tumor BRCA Status
March 24, 2021
Results of prospective, open-label trial of olaparib maintenance in patients with platinum-sensitive relapsed ovarian cancer continued to demonstrate efficacy of the PARP inhibitor in this setting.
ARIEL4 Trial Confirms PFS Benefit of Rucaparib in BRCA+ Relapsed Ovarian Cancer
March 20, 2021
An update from the phase 3 ARIEL4 trial presented at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer supports the continued use of rucaparib in patients with BRCA-mutant relapsed advanced ovarian cancer, based on progression-free survival and response data.
In B-Cell NHL, Off-the-Shelf NK Immunotherapy Shows Promise When Used With Chemotherapy and ASCT
February 19, 2021
Findings presented at the 2021 Transplant & Cellular Therapy Meetings indicate that patients with B-cell non-Hodgkin lymphoma may benefit from a type of natural killer immunotherapy added to chemotherapy and transplant.
Phase 3 Data Support Enfortumab Vedotin Benefit in Previously Treated Urothelial Carcinoma
February 13, 2021
Recently reported data continue to support the use of enfortumab vedotin in patients with advanced urothelial carcinoma who had previously been treated with chemotherapy and immunotherapy.
Advanced RCC Shows Response to Frontline Nivolumab/Cabozantinib, Regardless of the Presence of Sarcomatoid Features
February 13, 2021
Compared against sunitinib, nivolumab plus cabozantinib induced better outcomes in patients with advanced renal cell carcinoma and these results were seen in patients with and without sarcomatoid features.
Trastuzumab Deruxtecan Shows Antitumor Activity for Patients with HER2-Overexpressing NSCLC
January 29, 2021
Trastuzumab deruxtecan treatment demonstrated strong antitumor activity for patients with HER2-overexpressing NSCLC, regardless of HER2 expression levels, according to interim findings from the phase 2 DESTINY Lung-01 trial.
TAS-102 Plus Bevacizumab Leads to Improved OS in Patients With mCRC Ineligible for Intensive Therapy
January 17, 2021
When compared with standard capecitabine and bevacizumab therapy, patients with unresectable metastatic colorectal cancer saw an increase in overall and progression-free survival.
Surgical Risk Appears to Be Unaffected by Neoadjuvant Chemotherapy Use in Thoracic Esophageal Cancer
January 15, 2021
Patient's surgical risk for potentially resectable advanced thoracic esophageal cancer is not negatively impacted by neoadjuvant chemotherapy, study finds.